We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
+57.51%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$3.59B
AUM Growth
+$852M
Cap. Flow
-$15.9M
Cap. Flow %
-0.44%
Top 10 Hldgs %
60.96%
Holding
76
New
4
Increased
9
Reduced
2
Closed
9

Top Buys

Rank Stock Value
1
IDYA icon
IDEAYA Biosciences
IDYA
+$66.4M
2
JANX icon
Janux Therapeutics
JANX
+$33.7M
3
RVMD icon
Revolution Medicines
RVMD
+$31.9M
4
PVLA
Palvella Therapeutics
PVLA
+$11.8M
5
ALLK
Allakos
ALLK
+$11.7M

Top Sells

Rank Stock Value
1
SNDX icon
Syndax Pharmaceuticals
SNDX
+$45.3M
2
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$44M
3
IMVT icon
Immunovant
IMVT
+$39.7M
4
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
+$37M
5
MRUS
Merus
MRUS
+$30.1M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARAV
51
DELISTED
Aravive, Inc. Common Stock
ARAV
$6.03M 0.17%
4,784,214
– –
ELDN icon
52
Eledon Pharmaceuticals
ELDN
$259M
$5.93M 0.17%
4,326,710
+2,000,000
+86% +$4.17M
VIRX
53
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$5.1M 0.14%
3,614,662
– –
KRON
54
DELISTED
Kronos Bio
KRON
$4.84M 0.13%
+2,813,485
New +$4.47M
RAIN
55
DELISTED
Rain Oncology Inc. Common Stock
RAIN
$4.23M 0.12%
3,526,729
– –
ASLN
56
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
$3.83M 0.11%
+131,250
New +$4.06M
ELEV
57
DELISTED
Elevation Oncology
ELEV
$3.51M 0.1%
2,312,200
– –
PVLA
58
Palvella Therapeutics
PVLA
$2.05B
$3.41M 0.1%
257,623
+194,119
+306% +$11.8M
CRVS icon
59
Corvus Pharmaceuticals
CRVS
$1.09B
$3.14M 0.09%
1,370,947
– –
IMUX icon
60
Immunic
IMUX
$192M
$2.89M 0.08%
114,943
– –
IVA
61
Inventiva
IVA
$1.06B
$2.77M 0.08%
686,040
– –
MOLN
62
Molecular Partners
MOLN
$2.71M 0.08%
443,221
– –
MTEM
63
DELISTED
Molecular Templates, Inc.
MTEM
$2.4M 0.07%
333,104
– –
INFI
64
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$1.34M 0.04%
6,353,645
– –
RZLT icon
65
Rezolute
RZLT
$455M
$378K 0.01%
190,815
– –
GLMD icon
66
Galmed Pharmaceuticals
GLMD
$4.98M
$261K 0.01%
7,488
– –
NEUP
67
Neuphoria Therapeutics
NEUP
$21.1M
$178K 0.01%
6,748
– –
CRNX icon
68
Crinetics Pharmaceuticals
CRNX
$8.86B
– –
-2,736,613
Closed -$44M
ELTX icon
69
Elicio Therapeutics
ELTX
$76.2M
– –
-107,130
Closed -$621K
HLVX
70
DELISTED
HilleVax
HLVX
– –
-248,579
Closed -$4.11M
IMVT icon
71
Immunovant
IMVT
$7.98B
– –
-2,561,000
Closed -$39.7M
SNDX icon
72
Syndax Pharmaceuticals
SNDX
$1.68B
– –
-2,143,197
Closed -$45.3M
VRDN icon
73
Viridian Therapeutics
VRDN
$2.13B
– –
-168,000
Closed -$4.27M
WHWK
74
Whitehawk Therapeutics
WHWK
$189M
– –
-318,205
Closed -$2.3M
ALPN
75
DELISTED
Alpine Immune Sciences Inc
ALPN
– –
-858,339
Closed -$6.63M
1 2
3
4

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q2 2023 Portfolio in Review

As of Q2 2023, BVF Inc held 76 positions worth $3.59B, up 31% from $2.74B the previous quarter. Its ten largest holdings account for 61% of the portfolio.

BVF Inc's Q2 2023 filing shows 4 new, 9 increased, 2 reduced and 9 closed positions. Its largest new stake was TScan Therapeutics: 2,989,474 shares worth $7.47M. The largest sale was Syndax Pharmaceuticals, an estimated $45.3M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • BVF Inc's largest Q2 2023 buy was TScan Therapeutics: 2,989,474 shares worth $7.47M.
  • BVF Inc added most to IDEAYA Biosciences in Q2 2023, an estimated $66.4M increase.
  • BVF Inc's biggest Q2 2023 reduction was Merus, cutting an estimated $30.1M.
  • BVF Inc fully exited Syndax Pharmaceuticals in Q2 2023, selling an estimated $45.3M.
  • BVF Inc's ten largest holdings make up 61% of its $3.59B portfolio in Q2 2023.
  • BVF Inc opened 4 new positions and closed 9 in Q2 2023.
  • BVF Inc's portfolio value rose 31% quarter-over-quarter to $3.59B.

Based on BVF Inc's 13F filing for Q2 2023, filed 14 Aug 2023.